Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Sutro Biopharma (STRO) has 7 years of Total Debt data on file, last reported at $4.1 million in Q4 2023.

• For the quarter ending Q4 2023, Total Debt fell 75.04% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2023 stood at $4.1 million (down 75.04% YoY), and the FY2023 full-year result was $4.1 million, down 75.04% from the prior year.
• Total Debt retreated to $4.1 million in Q4 2023, from $7.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $25.3 million in Q1 2022 to a low of $4.1 million in Q4 2023.
• A 5-year average of $18.1 million and a median of $20.8 million in 2022 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 148.53% in 2020 and plunged 75.04% in 2023, its largest moves.
• Tracing STRO's Total Debt over 5 years: stood at $9.9 million in 2019, then jumped by 148.53% to $24.5 million in 2020, then rose by 2.31% to $25.1 million in 2021, then sank by 35.21% to $16.3 million in 2022, then sank by 75.04% to $4.1 million in 2023.
• Business Quant data shows STRO's Total Debt at $4.1 million in Q4 2023, $7.1 million in Q3 2023, and $10.2 million in Q2 2023.